Abbott Taps Genentech Oncology Expertise For Two Phase I Compounds
Drug makers will collaborate on research and development of a Bcl-2 protein antagonist and VEGFR-based kinase inhibitor.
Drug makers will collaborate on research and development of a Bcl-2 protein antagonist and VEGFR-based kinase inhibitor.